Screener / SEC EDGAR /CIK 0001061983 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Cytokinetics Inc CYTK

Compare with peers Embed
Planned sales, announced before they happen

15 trading plans running, 30 Form 144 notices for $48.9M

10-Q, 10-K and Form 144
Plans running now 15 Robert I. Blum, Robert A. Harrington, Sung H. Lee, Andrew Callos, Fady I. Malik, John T. Henderson, B. Lynne Parshall, Robert E. Landry, Wendell Wierenga, Edward M. Kaye, Fady Malik, Sung Lee
Plans adopted 26 reported since May 5, 2023 Form 144 notices 30 $48.9M the sellers expected to sell

What CYTK's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Mar 2, 2026 to May 16, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Robert I. Blum
President and Chief Executive Officer
Adopted 10b5-1 plan Sep 11, 2026 10-Q Nov 4, 2026
Robert A. Harrington
member of our board of directors
Adopted 10b5-1 plan Aug 31, 2026 10-Q Nov 4, 2026
Sung H. Lee
Executive Vice President, Chief Financial Officer
Adopted 10b5-1 plan Aug 31, 2026 10-Q Nov 4, 2026
Andrew Callos
Executive Vice President, Chief Commercial Officer
Adopted 10b5-1 plan Aug 25, 2026 10-Q Nov 4, 2026
Fady I. Malik
Executive Vice President, Research and Development
Adopted 10b5-1 plan Aug 24, 2026 10-Q Nov 4, 2026
John T. Henderson
Chairman of our board of directors
Adopted 10b5-1 plan Aug 24, 2026 10-Q Nov 4, 2026
B. Lynne Parshall
member of our board of directors
Adopted 10b5-1 plan Aug 10, 2026 10-Q Nov 4, 2026
Robert E. Landry
Adopted 10b5-1 plan Jun 12, 2026 10-Q Aug 6, 2026
Wendell Wierenga
Adopted 10b5-1 plan Jun 10, 2026 10-Q Aug 6, 2026
Edward M. Kaye
M.D
Adopted 10b5-1 plan Mar 2, 2026 10-Q May 5, 2026
Robert Blum
President & Chief Executive Officer
Ended other arrangement Dec 31, 2025 10-Q May 10, 2024
Robert I. Blum
President & Chief Executive Officer
Adopted 10b5-1 plan Dec 24, 2025 10-K Feb 26, 2026
Fady Malik
Executive Vice President, Research & Development
Adopted 10b5-1 plan Dec 23, 2025 10-K Feb 26, 2026
Sung Lee
Executive Vice President & Chief Financial Officer
Adopted 10b5-1 plan Dec 23, 2025 10-K Feb 26, 2026
Robert I. Blum
President & Chief Executive Officer
Ended 10b5-1 plan Nov 14, 2025 10-K Feb 27, 2025
Andrew Callos
Adopted 10b5-1 plan Sep 5, 2025 10-Q Nov 5, 2025
John T. Henderson
Adopted 10b5-1 plan Sep 2, 2025 10-Q Nov 5, 2025
B. Lynne Parshall
Adopted 10b5-1 plan Aug 20, 2025 10-Q Nov 5, 2025
Wendell Wierenga
Adopted 10b5-1 plan May 14, 2025 10-Q Aug 7, 2025
Robert A. Harrington
Adopted 10b5-1 plan May 9, 2025 10-Q Aug 7, 2025
Wendell Wierenga
Director, Chair of the Science and Technology Committee
Ended other arrangement May 9, 2025 10-Q May 10, 2024
Edward M. Kaye
M.D
Adopted 10b5-1 plan Mar 6, 2025 10-Q May 6, 2025
Andrew Callos
Executive Vice President, Chief Commercial Officer
Ended other arrangement Mar 4, 2025 10-Q May 10, 2024
Edward M. Kaye
Director
Ended other arrangement Mar 4, 2025 10-Q May 10, 2024
Fady Malik
Executive Vice President, Research and Development
Ended other arrangement Dec 13, 2024 10-Q May 10, 2024
Andrew Callos
Executive Vice President, Chief Commercial Officer
Adopted 10b5-1 plan Dec 12, 2024 10-K Feb 27, 2025
Santo J. Costa
Director, Chair of the Compensation and Talent Committee
Ended other arrangement Dec 5, 2024 10-Q May 10, 2024
Muna Bhanji
Director
Adopted 10b5-1 plan Nov 18, 2024 10-K Feb 27, 2025
Robert Harrington
Director
Adopted 10b5-1 plan Nov 8, 2024 10-K Feb 27, 2025
Robert Wong
Vice President, Chief Accounting Officer
Ended other arrangement Sep 30, 2024 10-Q May 10, 2024
B. Lynne Parshall
Director, Chair of the Audit Committee
Ended other arrangement Sep 20, 2024 10-Q May 10, 2024
Fady Malik
Executive Vice President, Research & Development
Adopted 10b5-1 plan Sep 16, 2024 10-K Feb 27, 2025
Fady Malik
Executive Vice President, Research and Development
Adopted 10b5-1 plan Sep 16, 2024 10-Q Nov 7, 2024
John T. Henderson
Chairman of our Board of Directors
Adopted 10b5-1 plan Sep 11, 2024 10-K Feb 27, 2025
John T. Henderson
Chairman of our Board of Directors
Adopted 10b5-1 plan Sep 11, 2024 10-Q Nov 7, 2024
Robert Harrington
Director
Ended other arrangement Jul 31, 2024 10-Q May 10, 2024
Muna Bhanji
Director
Ended other arrangement Jul 24, 2024 10-Q May 10, 2024
John T. Henderson
Chairman of our Board of Directors
Ended other arrangement May 25, 2024 10-Q Nov 3, 2023
Wendell Wierenga
Member of our Board of Directors
Ended other arrangement May 21, 2024 10-Q Nov 3, 2023
Fady I. Malik
Vice President, Research and Development
Ended other arrangement May 8, 2024 10-Q Nov 3, 2023
Ching W. Jaw
Senior Vice President & Chief Financial Officer
Ended 10b5-1 plan Jun 30, 2023 10-Q Aug 3, 2023
John T. Henderson
Chairman of our Board of Directors
Ended 10b5-1 plan May 15, 2023 10-Q Aug 3, 2023
Show the other 34 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 5, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 9, 2026 B LYNNE PARSHALL
Director
5,000 $268K
Oct 20, 2026 FADY MALIK
Officer
16,386 $1.0M
Oct 13, 2026 ROBERT BLUM
Director, Officer
22,500 $1.4M
Sep 15, 2026 Robert I. Blum
President, CEO, Director
97,926 $7.1M
Sep 11, 2026 ROBERT LANDRY
Director
2,000 $147K
Sep 1, 2026 B LYNNE PARSHALL
Director
5,000 $355K
Jul 30, 2026 ANDREW CALLOS
Officer
24,000 $1.9M
Jul 7, 2026 FADY MALIK
Officer
24,500 $2.1M
Jul 1, 2026 ROBERT BLUM
Director, Officer
52,500 $4.5M
Jun 29, 2026 Sung Lee
Officer
9,503 $781K
Jun 26, 2026 Sung Lee
Officer
6,695 $541K
Jun 24, 2026 Sung Lee
Officer
38,730 $3.1M
Jun 1, 2026 EDWARD KAYE
Director
2,933 $225K
May 5, 2026 WENDELL WIERENGA
Director
4,032 $266K
May 5, 2026 JOHN HENDERSON
Director
20,000 $1.3M
May 5, 2026 SUNG LEE
Officer
23,906 $1.6M
Apr 15, 2026 ANDREW CALLOS
Officer
79,639 $5.3M
Apr 7, 2026 FADY MALIK
Officer
22,000 $1.4M
Apr 1, 2026 ROBERT BLUM
Director, Officer
45,000 $3.0M
Mar 31, 2026 ANDREW CALLOS
Officer
3,639 $229K
Mar 18, 2026 ANDREW CALLOS
Officer
1,930 $120K
Mar 16, 2026 ANDREW CALLOS
Officer
1,709 $103K
Mar 2, 2026 B LYNNE PARSHALL
Director
10,000 $622K
Jan 2, 2026 ANDREW CALLOS
Officer
59,570 $3.8M
Dec 29, 2025 ANDREW CALLOS
Officer
1,809 $114K
Dec 22, 2025 WENDELL WIERENGA
Director
20,000 $1.3M
Dec 5, 2025 ANDREW CALLOS
Officer
53,528 $3.6M
Dec 2, 2025 JOHN T HENDERSON
Director
8,750 $578K
Dec 1, 2025 EDWARD KAYE
Director
28,064 $1.9M
Nov 19, 2025 B LYNNE PARSHALL
Director
5,000 $331K
Show the other 22 notices

From the Form 144 XML filed with the SEC, since Nov 19, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CYTK/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.